Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Single-cell profiling reveals teclistamab-induced reshaping of nasopharyngeal immunity in multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

TKTobias KrammerNANazia AfrinKKK. Martin Kortüm

Discussion

Loading...

Member takes

Overview

Single-cell RNA sequencing reveals immunosuppression and immune cell changes in myeloma patients, indicating challenges in combating infections.

Key Points

  • The study aims to investigate the effects of teclistamab on nasopharyngeal immunity in multiple myeloma patients.
  • Conducted deep nasal swabs in 36 RRMM patients treated with teclistamab and 13 controls receiving daratumumab.
  • Performed single-cell RNA sequencing on nasal cells using 10x Genomics chemistry.
  • Conducted longitudinal sampling to observe changes over the treatment timeline.
  • Single-cell RNA sequencing identified 17 distinct immune and epithelial cell populations.
  • Both teclistamab and daratumumab groups lacked B and dendritic cells in the nasopharynx compared to healthy individuals.
  • Teclistamab treatment resulted in the emergence of exhausted CD4⁺ T cells and changes in local mucosal gene expression.

Cite This Study

Krammer et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d3f9https://doi.org/10.1182/blood-2025-5698
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The resistec study: Dissecting immune correlates of resistance and response to teclistamab in real-world multiple myeloma2025
  2. 2Longitudinal mechanisms of response, resistance and relapse to teclistamab in multiple myeloma: results from MajesTEC-12026
  3. 3Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study2024 · 63 citations
  4. 4Real-world outcomes of teclistamab for the treatment of relapsed/refractory multiple myeloma at UC San Diego Health: A single-institution experience.2024 · 5 citations
  5. 5Real-world analysis of infection timing and burden in multiple myeloma patients treated with teclistamab2025